A reevaluation of the exclusion criteria used in antidepressant efficacy trials.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Journal of Psychiatry

• Publication date

  2002-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/APPI.AJP.159.2.191PMID 11823258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Moclobemide and placebo in mild major depression: a double-blind randomized trial

  2005cited by this paper
• Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

  2002cited by this paper
• Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.

  2001cited by this paper
• Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.

  2000cited by this paper
• Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.

  2000cited by this paper
• A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

  2000cited by this paper
• Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

  2000cited by this paper
• Fluoxetine in early poststroke depression: a double-blind placebo-controlled study.

  2000cited by this paper
• Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial.

  2000cited by this paper
• Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial

  2000cited by this paper
• Treatment of major depression in the context of panic disorder.

  1999cited by this paper
• Fluoxetine versus placebo for the marijuana use of depressed alcoholics.

  1999cited by this paper
• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression?

  1999cited by this paper
• Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.

  1998cited by this paper
• Placebo-controlled study of sertraline in depressed recently abstinent alcoholics.

  1998cited by this paper
• Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.

  1998cited by this paper
• Therapeutic trial participants: where do we find them and what does it cost?

  1997cited by this paper
• Treatment‐refractory depression: Definitions and characteristics

  1997cited by this paper
• Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.

  1997cited by this paper
• Moclobemide and imipramine in chronic depression (dysthymia): an international double‐blind, placebo‐controlled trial

  1997cited by this paper
• Effects of Nortriptyline on Depression and Glycemic Control in Diabetes: Results of a Double-blind, Placebo-controlled Trial

  1997cited by this paper
• Patients excluded from an antidepressant efficacy trial.

  1996cited by this paper
• Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.

  1996cited by this paper
• Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial.

  1996cited by this paper
• A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression.

  1996cited by this paper
• Maintenance therapy of persons with schizophrenia.

  1996cited by this paper
• The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.

  1996cited by this paper
• Impact of Physical Illness on Quality of Life and Antidepressant Response in Geriatric Major Depression

  1996cited by this paper
• Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.

  1996cited by this paper
• Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.

  1995cited by this paper
• Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.

  1995cited by this paper
• Characteristics of desipramine-refractory depression.

  1994cited by this paper
• Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?

  1994cited by this paper
• Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.

  1994cited by this paper
• Cluster a personality disorder: a marker of worse treatment outcome of major depression?

  1994cited by this paper
• The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies.

  1994cited by this paper
• Effective Treatment of Poststroke Depression With the Selective Serotonin Reuptake Inhibitor Citalopram

  1994cited by this paper
• The Time Course of Nonchronic Major Depressive Disorder: Uniformity Across Episodes and Samples

  1994cited by this paper
• Clinical correlates of PET- and SPECT-identified defects in dementia.

  1994cited by this paper
• Personality pathology and response to somatic treatments for major depression: A critical review

  1994cited by this paper
• Dysfunctional attitudes in major depression. Changes with pharmacotherapy.

  1994cited by this paper
• Severity of depression and response to fluoxetine

  1993cited by this paper
• Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.

  1993cited by this paper
• Anxiety disorders and anxiety symptoms in a clinic sample of seasonal and non-seasonal depressives.

  1993cited by this paper
• Severity of depression and response to fluoxetine

  1993cited by this paper
• Efficacy of phenelzine and haloperidol in borderline personality disorder.

  1993cited by this paper
• Effect size as a measure of symptom-specific drug change in clinical trials.

  1993cited by this paper
• Anxious and nonanxious depression.

  1993cited by this paper
• Desipramine treatment of cocaine dependence in methadone-maintained patients.

  1992cited by this paper
• Melancholic/endogenous depression and response to somatic treatment and placebo.

  1992cited by this paper
• Personality traits and response to desipramine.

  1992cited by this paper
• Can We Predict the Persistence of Depression?

  1992cited by this paper
• Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects.

  1992cited by this paper
• Clinical features of depressed patients who do and do not improve with placebo.

  1992cited by this paper
• Basic advances in serotonin pharmacology.

  1992cited by this paper
• Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy.

  1992cited by this paper
• The course of depression in adult outpatients. Results from the Medical Outcomes Study.

  1992cited by this paper
• Can mildly depressed outpatients with atypical depression benefit from antidepressants?

  1992cited by this paper
• Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease.

  1992cited by this paper
• The effect of paroxetine on anxiety and agitation associated with depression.

  1992cited by this paper
• A placebo-controlled trial of paroxetine in the treatment of major depression.

  1992cited by this paper
• Chronicity of depressive episode in relation to antidepressant-placebo response.

  1991cited by this paper
• 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression).

  1991cited by this paper
• Desipramine treatment of alcoholism.

  1991cited by this paper
• A Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients

  1991cited by this paper
• Follow-up and family study of anxious depression.

  1991cited by this paper
• Antidepressant pharmacotherapy of depression associated with multiple sclerosis.

  1990cited by this paper
• Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression.

  1990cited by this paper
• Treatment of posttraumatic stress disorder with amitriptyline and placebo.

  1990cited by this paper
• Effects of pill-giving on maintenance of placebo response in patients with chronic mild depression.

  1990cited by this paper
• A controlled trial of desipramine in 18 men with posttraumatic stress disorder.

  1989cited by this paper
• The introductory placebo washout: a retrospective evaluation.

  1989cited by this paper
• Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.

  1989cited by this paper
• Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.

  1989cited by this paper
• Double-blind trial of imipramine in Alzheimer's disease patients with and without depression.

  1989cited by this paper
• Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.

  1989cited by this paper
• The influence of alcoholism on the course of depression.

  1989cited by this paper
• Consensus Conference on the Methodology of Clinical Trials of Antidepressants, Zurich, march 1988: Report of the Consensus Committee

  1989cited by this paper
• Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data.

  1988cited by this paper
• Treatment Resistant Depression: A Clinical Perspective*

  1988cited by this paper
• Predictors of placebo response in depression.

  1988cited by this paper
• Placebo response in depression: a search for predictors.

  1988cited by this paper
• Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice.

  1988cited by this paper
• Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications.

  1988cited by this paper
• Are Tricyclic Antidepressants Useful for Mild Depression? A Placebo controlled Trial

  1988cited by this paper
• Imipramine treatment for chronic depression.

  1988cited by this paper
• Double depression and episodic major depression: demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome.

  1988cited by this paper
• The importance of Axis II in patients with major depression. A controlled study.

  1988cited by this paper
• Placedo response in depression: A search for predictors

  1988cited by this paper
• Predictors of placebo response in depression.

  1988cited by this paper
• Baseline characteristics of 10-day placebo washout responders in antidepressant trials.

  1987cited by this paper
• Which depressions respond to placebo?

  1986cited by this paper
• Treatment of Depression in Chronic Cocaine and Phencyclidine Abuse With Desipramine

  1986cited by this paper
• ECT response in depressed patients with and without a DSM-III personality disorder.

  1986cited by this paper
• Simultaneous panic and depressive disorder: response to antidepressant treatments.

  1986cited by this paper
• Prediction of the Amitriptyline Response: Psychopathology Versus Neuroendocrinology

  1986cited by this paper
• Tricyclic nonresponders: phenomenology and treatment.

  1986cited by this paper
• Trimipramine in physical illness with depression.

  1985cited by this paper
• Efficacy and safety of mianserin in the treatment of depression of women with cancer

  1985cited by this paper

• From Billing Codes to Breakthroughs: Filtering Signal From Noise in Electronic Medical Records-Based Research.

  2025cites this paper
• Effect of selective serotonin reuptake inhibitor treatment following diagnosis of depression on suicidal behaviour risk: a target trial emulation

  2023cites this paper
• Not sad enough for a depression trial? A systematic review of depression measures and cut points in clinical trial registrations: Systematic review of depression measures and cut points.

  2021cites this paper
• Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study

  2021cites this paper
• Risk of seizures with antidepressants: what is the evidence?

  2020cites this paper
• Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis

  2019cites this paper
• Have Treatment Studies of Depression Become Even Less Generalizable? Applying the Inclusion and Exclusion Criteria in Placebo-Controlled Antidepressant Efficacy Trials Published over 20 Years to a Clinical Sample

  2019cites this paper
• Can knowledge of Placebo and Nocebo Mechanisms Help Improve Randomized Clinical Trials?

  2018cites this paper
• Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

  2018cites this paper
• Depression care among adults with co-occurring major depressive episodes and substance use disorders in the United States.

  2017cites this paper
• Brain Mechanisms of the Placebo Effect: An Affective Appraisal Account.

  2017cites this paper
• Depression and Survival in a 17-Year Longitudinal Study of People With HIV: Moderating Effects of Race and Education

  2017cites this paper
• Maintenance of Blinding in Clinical Trials and the Implications for Studying Analgesia Using Cannabinoids

  2016cites this paper
• Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant

  2016cites this paper
• How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment

  2015cites this paper
• Efficacy of Atypical Antipsychotics to Treat Behavioral and Psychological Symptoms of Dementia in Nursing Home Residents: A Systematic Review of the Evidence from Randomized Controlled Trials

  2015cites this paper
• Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder.

  2015cites this paper
• Protecting the Market

  2015cites this paper
• A Review of the Nature and Impact of Exclusion Criteria in Depression Treatment Outcome Research

  2015cites this paper
• Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.

  2014cites this paper
• A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine Xr) monotherapy in patients with major depressive disorder

  2014influential citation
• Effect of variability in the 7‐day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: An ACTTION study

  2014cites this paper
• Does pain interfere with antidepressant depression treatment response and remission in patients with depression and pain? An evidence-based structured review.

  2014cites this paper
• Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors

  2014cites this paper
• Recurrent Inguinal Hernia Repair: What is the Evidence of Case Series? A Meta-Analysis and Metaregression Analysis

  2014cites this paper
• A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine Xr) monotherapy in patients with major depressive disorder

  2014influential citation
• A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

  2014influential citation
• Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial.

  2013cites this paper
• Psychotropic drug epidemiology and systematic reviews of randomised clinical trials: The roads travelled, the roads ahead

  2013cites this paper
• Peer Reviewed Title: Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: A randomized controlled trial

  2013cites this paper
• Improving study design for antidepressant effectiveness assessment

  2013cites this paper
• Influence of sociodemographic and socioeconomic features on treatment outcome in RCTs versus daily psychiatric practice

  2013cites this paper
• The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients

  2013cites this paper
• A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder.

  2012cites this paper
• Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue

  2012cites this paper
• Generalizability of systematic reviews of the effectiveness of health care interventions to primary health care: concepts, methods and future research.

  2012cites this paper
• The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice

  2012cites this paper
• Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data.

  2011cites this paper
• Antidepressant Response in Major Depressive Disorder: A Meta-Regression Comparison of Randomized Controlled Trials and Observational Studies

  2011cites this paper
• Treatment of Major Depressive Disorder and Dysthymic Disorder With Antidepressants in Patients With Comorbid Opiate Use Disorders Enrolled in Methadone Maintenance Therapy: A Meta-Analysis

  2011cites this paper
• Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials

  2011cites this paper
• Benchmarking of cognitive-behavioral therapy for depression in efficacy and effectiveness studies—How do exclusion criteria affect treatment outcome?

  2011influential citation
• How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey

  2011cites this paper
• Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.

  2011cites this paper
• Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

  2011cites this paper
• The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review

  2010influential citation
• A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.

  2010cites this paper
• Transcranial Magnetic Stimulation for the Treatment of Major Depression: Clinical, Economic, and Practical Issues Part II

  2010cites this paper
• The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice

  2010cites this paper
• Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials.

  2010cites this paper
• First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial.

  2010cites this paper
• Determinanten für den Ein- und Ausschluss von Patienten bei Phase III- und IV-Studien an einer psychiatrisch-psychotherapeutischen Versorgungsklinik

  2009cites this paper
• Development of a patient-reported assessment to identify placebo responders in a generalized anxiety disorder trial.

  2009cites this paper
• EPA but Not DHA Appears To Be Responsible for the Efficacy of Omega-3 Long Chain Polyunsaturated Fatty Acid Supplementation in Depression: Evidence from a Meta-Analysis of Randomized Controlled Trials

  2009cites this paper
• Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

  2008cites this paper
• Motivation and the placebo response : predicting non-specific therapeutic benefits from the concordance of therapeutic rituals with high-level goals

  2008cites this paper
• Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts

  2008cites this paper
• Consistency of the placebo effect.

  2008cites this paper
• A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response.

  2008cites this paper
• Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

  2008cites this paper
• Genetics of mood disorders : from pharmacogenetics to disease genetics

  2008cites this paper
• Generalizability of clinical trials for cannabis dependence to community samples.

  2008cites this paper
• The Use and Clinical Significance of Transcranial Magnetic Stimulation in the Treatment of Major Depression

  2007cites this paper
• Evidence-based treatment of psychiatric disorders with comorbid medical illnesses: the need for large simple clinical trials.

  2007cites this paper
• Durability of antidepressant response to vagus nerve stimulation (VNS).

  2007cites this paper
• An analysis of the exclusion criteria used in observational pharmacoepidemiological studies

  2007cites this paper
• The influence of educational information on depressed outpatients treated with escitalopram: A semi-naturalistic study

  2007cites this paper
• Relevance of Exclusion Criteria in Antidepressant Clinical Trials: A Replication Study

  2007influential citation
• Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis

  2007cites this paper
• Further evidence for individual differences in placebo responding: an interactionist perspective.

  2007cites this paper
• Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials

  2007cites this paper
• Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases

  2007cites this paper
• Mirtazapine naturalistic depression study (in Sweden)—MINDS(S): clinical efficacy and safety

  2006cites this paper
• Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures.

  2006cites this paper
• Rational antidepressant selection: applying evidence-based medicine to complex real-world patients.

  2006cites this paper
• Interpersonal psychotherapy for elderly patients in primary care.

  2006cites this paper
• Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit.

  2006cites this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cites this paper
• Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.

  2006cites this paper
• Panacea or Placebo: The Historical Quest for Medications to Treat Depression

  2006cites this paper
• Annals Journal Club: It’s Time to Get RADICAL

  2006cites this paper
• Experience is a biochemical intervention: reconceptualizing the "biologically based mental illness".

  2005cites this paper
• Antidepressant drug prescribing among elderly subjects: a population‐based study

  2005cites this paper
• Psychotropic drug epidemiology: The road travelled, the road ahead

  2005cites this paper
• Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial.

  2005cites this paper
• Invitation to a dialogue between researchers and clinicians about evidence-based behavioral medicine

  2005cites this paper
• Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain

  2005cites this paper
• Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research

  2005cites this paper
• Placebo: The Best Pill of All

  2005cites this paper
• Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?

  2004cites this paper
• Which factors influence psychiatrists' selection of antidepressants?

  2004cites this paper
• How real are patients in placebo-controlled studies of acute manic episode?

  2004cites this paper
• Randomized controlled trials: still somewhat immature

  2004cites this paper
• The maturation of randomised controlled trials in mental health

  2004influential citation
• Exclusion Criteria Used in Antidepressant Efficacy Trials: Consistency Across Studies and Representativeness of Samples Included

  2004cites this paper
• Benefits and burdens of placebos in psychiatric research

  2003cites this paper
• How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial?

  2003cites this paper
• Impact of Comorbidity on Treatment Response to Paroxetine in Pediatric Obsessive-Compulsive Disorder: Is the Use of Exclusion Criteria Empirically Supported in Randomized Clinical Trials?

  2003cites this paper
• How accurate are patients in reporting their antidepressant treatment history?

  2003cites this paper
• The Future of Consultation–Liaison Psychiatry∗

  2003cites this paper